Sankyo Company, Limited

Snow Brand Milk Products Co., Ltd.

Daiichi Sankyo Company, Limited

Nobuyuki Shima

Kanji Higashio

Eisuke Tsuda

Masaaki Goto

Fumie Kobayashi

Kazuki Yano

Tomonori Morinaga

Hisataka Yasuda

Nobuaki Nakagawa

Masatsugu Ueda

Shin'ichi Mochizuki

Kyoji Yamaguchi

Masahiko Kinosaki

Naohiro Washida

Akihiro Tomoyasu

Ken Takahashi

Masaya Nagao

Fumiko Oogaki

Yasuharu Itagaki

Shinjiro Mitsuda

Hiroaki Masunaga

Akihiko Murakami

Hiroaki Takaoka

Shin′ichi Mochizuki

Reiko Takahira

Nobuaki Nishiura Heights 2-4 Nakagawa

Tomonori 11-12 Saiwaicho 3-Chome Morinaga

Akihiro Sk-Mansion Tomoyasu

Ken Nishiura Heights 1-4 Takahashi

Eisuke Diapalace Jichiidai 5-Bankan 407 Tsuda

Kazuki Nishiura Heights 3-1 Yano

Novel proteins and polypeptides binding to osteoclastogenesis inhibitory factor (OCIF) (OCIF-binding molecules, OBMs) and nucleic acids encoding these proteins and polypeptides are provided. Processes for producing these proteins, polypeptides, and nucleic acid molecules by genetic engineering are provided. Medicinal compounds are provided which comprise proteins and nucleic acids according to the invention, as well as proteins which bind to OBM, including anti-OBM antibodies. These compounds may be used for the treatment of bone disease.

Methods of reducing bone absorption comprising administering an antibody that binds OBM

A protein which inhibits osteoclast differentiation and/or maturation and a method for producing the protein. The protein is produced by human embryonic lung fibroblasts and has a molecular weight of about 60 kD and about 120 kD under non-reducing conditions and about 60 kD under reducing conditions on SDS-polyacrylamide gel electrophoresis. The protein can be isolated and purified from the culture medium of fibroblasts. Furthermore, the protein can be produced by gene engineering. The present invention includes cDNA for producing the protein by gene engineering, antibodies having specific affinity for the protein or a method for determining protein concentration using these antibodies.

Nucleic acid molecules encoding osteoclastogenesis inhibitory factor proteins

The present invention relates to a novel protein which binds to Osteoclastogenesis Inhibitory Factor (OCIF-binding molecule; OBM), a process for preparing the same, DNA encoding said protein, a protein having an amino acid sequence encoded by this DNA, a method for producing said protein by genetic engineering technique, and a pharmaceutical composition containing said protein. In addition, screening methods for a substance for controlling expression of said protein using said protein and the DNA, a substance which inhibits or modulates the biological activity of said protein, or a receptor which transmits the action of said protein through binding to said protein, the substance obtained by the screening methods, and a pharmaceutical composition which contains this substance are disclosed. An antibody for said protein, a process for preparing the same, a measuring method of said protein using the antibody, and a medicine comprising the antibody are also disclosed.

Antibodies to OCIF-binding molecules

A protein which inhibits osteoclast differentiation and/or maturation and a method of production of the protein. The protein is produced by human embryonic lung fibroblasts and has molecular weight of about 60 kD and about 120 kD under non-reducing conditions and about 60 kD under reducing conditions on SDS-polyacrylamide gel electrophoresis, respectively. The protein can be isolated and purified from culture medium of the said fibroblasts. Furthermore, the protein can be produced by gene engineering. The present invention includes cDNA for producing the protein by gene engineering, antibodies having specific affinity to the protein or a method for determination of the protein concentration using the antibodies.

Methods for using the osteoclastogenesis inhibitory factor (OCIF) protein

Proteins and methods for producing the proteins

The present invention relates to a novel protein which binds to Osteoclastogenesis Inhibitory Factor (OCIF-binding molecule; OBM), a process for preparing the same, DNA encoding said protein, a protein having an amino acid sequence encoded by this DNA, a method for producing said protein by genetic engineering technique, and a pharmaceutical composition containing said protein. In addition, screening methods for a substance for controlling expression of said protein using said protein and the DNA, a substance which inhibits or protein through binding to said protein, the substance obtained by the screening methods, and a pharmaceutical composition which contains this substance are disclosed. An antibody for said protein, a process for preparing the same, a measuring method of said protein using the antibody, and a medicine comprising the antibody are also disclosed.

Methods for identifying a substance which specifically binds to an osteoclastogenesis inhibitory factor-binding molecule and modulates the biological activity thereof

A protein which inhibits osteoclast diffraction and/or maturation and a method for producing the protein. The protein is produced by human embryonic lung fibroblasts and has a molecular weight of about 60 kD and about 120 kD under non-reducing conditions and about 60 kD under reducing conditions an SDS-polyacrylamide gel electrophoresis. The protein can be isolated and purified from the culture medium of fibroblasts. Furthermore, the protein can be produced by gene engineering. The present invention includes cDNA for producing the protein by gene engineering, antibodies having specific affinity for the protein or a method for determining protein concentration using these antibodies.

Monoclonal antibodies that bind OCIF

A protein which inhibits osteoclast differentiation and/or maturation and a method for producing the protein. The protein is produced by human embryonic lung fibroblasts and has a molecular weight of about 60 kD and about 120 kD under non-reducing conditions and about 60 kD under reducing conditions on SDS-polyacrylamide gel electrophoresis[[, respectively]]. The protein can be isolated and purified from the culture medium of fibroblasts. Furthermore, the protein can be produced by gene engineering. The present invention includes cDNA for producing the protein by gene engineering, antibodies having specific affinity for the protein or a method for determining protein concentration using these antibodies.

The new glycoprotein, which possesses an anti-tumor activity, a leukemia cell differentiation inducing activity, a cellular immunology enhancing activity, a vascular endothelial cell growth stimulating activity and a hepatocyte growth stimulating activity, can be obtained.

Human-derived glycoprotein, biologically active factor which includes glycoprotein, and pharmaceutical product which comprises biologically active factor as active component

This invention relates to a monoclonal antibody having affinity to human TCF-II without any affinity to HGF and determination or purification methods of TCF-II using the antibody. The monoclonal antibody can be obtained by adding a blocking solution containing a surface active agent to the culture medium containing monoclonal antibody to block antibodies other than said monoclonal antibody, followed by reaction with a solid phase antigen, TCF-II. Human TCF-II can be selectively and effectively purified or determined without any influence of the presence of HGF by using the antibody.

Monoclonal antibody

Modified tumor cytotoxic factor (TCF) and DNA encoding such

Human derived glycoprotein, biologically active factor which includes

Plasmids containing DNA encoding the amino acid sequence of TCF-II and

Growing community of inventors

Tochigi, Japan

Nobuyuki Shima